Delightedly, in HR-positive BC cells, the SERPINA3 overexpression group seemed to own stronger proliferation viability than the control group with the treatment of cisplatin in MCF-7 cells (P < 0.05, Fig. 9b), also in T-47D cells (P < 0.05, Online Resource 5b). Here, SERPINA3 is linked to breast cancer.